Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aditxt Purchased $2.28M Of Evofem Series F-1 Convertible Preferred Stock, The Final Investment In Evofem Stipulated Under The A&R Merger Agreement

Author: Benzinga Newsdesk | October 28, 2024 07:17am

Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today announced the achievement of a key milestone under the Amended and Restated Merger Agreement, as amended (the "A&R Merger Agreement") toward completion of its intended acquisition of women's health innovator Evofem Biosciences, Inc. ("Evofem") (OTCQB:EVFM).

Today, Aditxt purchased $2.28 million of Evofem Series F-1 convertible preferred stock. This is the final investment in Evofem stipulated under the A&R Merger Agreement.

Posted In: ADTX EVFM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist